290.65 -0.65 (-0.22%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
288.0
Today’s High
296.0
52 Week Low
227.0
52 Week High
381.25
288.60 -2.90 (-0.99%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
287.8
Today’s High
296.25
52 Week Low
226.95
52 Week High
381
Key Metrics
- Market Cap (In Cr) 7055.55
- Beta 0.65
- Div. Yield (%) 0.26
- P/B 2.8
- TTM P/E 15.5
- Peg Ratio 3.2
- Sector P/E 28.39
- D/E -
- Open Price 290.05
- Prev Close 291.3
Analysis
Price Analysis
-
1 Week-5.72%
-
3 Months-22.62%
-
6 Month-7.28%
-
YTD-8.56%
-
1 Year-6.22%
Risk Meter
- 29% Low risk
- 29% Moderate risk
- 29% Balanced Risk
- 29% High risk
- 29% Extreme risk
Recos
8 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 1
- Buy
- 5
- Strong Buy
- 2
Granules India News
Granules India gets FDA approval for new drug to get rid from bothersome mucus
1 min read . 26 Aug 2022
USFDA issues 3 observations to Granules India arm in its pre-approval inspection
1 min read . 31 Jan 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 3764.92
- Selling/ General/ Admin Expenses Total
- 1081.58
- Depreciation/ Amortization
- 158.63
- Other Operating Expenses Total
- 14.58
- Total Operating Expense
- 3190.03
- Operating Income
- 574.89
- Net Income Before Taxes
- 558
- Net Income
- 412.76
- Diluted Normalized EPS
- 16.74
- Period
- 2022
- Total Assets
- 4512.9
- Total Liabilities
- 1926.36
- Total Equity
- 2586.53
- Tangible Book Valueper Share Common Eq
- 92.13
- Period
- 2022
- Cashfrom Operating Activities
- 332.05
- Cashfrom Investing Activities
- -380.11
- Cashfrom Financing Activities
- 190
- Net Changein Cash
- 142.88
- Period
- 2021
- Total Revenue
- 3237.54
- Selling/ General/ Admin Expenses Total
- 930.82
- Depreciation/ Amortization
- 151.46
- Other Operating Expenses Total
- 9.79
- Total Operating Expense
- 2525.18
- Operating Income
- 712.36
- Net Income Before Taxes
- 704.36
- Net Income
- 549.46
- Diluted Normalized EPS
- 21.99
- Period
- 2021
- Total Assets
- 3713.45
- Total Liabilities
- 1540.18
- Total Equity
- 2173.27
- Tangible Book Valueper Share Common Eq
- 75.03
- Period
- 2021
- Cashfrom Operating Activities
- 432.48
- Cashfrom Investing Activities
- -277.14
- Cashfrom Financing Activities
- -299.31
- Net Changein Cash
- -144.09
- Period
- 2020
- Total Revenue
- 2598.65
- Selling/ General/ Admin Expenses Total
- 731.02
- Depreciation/ Amortization
- 136.95
- Other Operating Expenses Total
- 6.68
- Total Operating Expense
- 2182.3
- Operating Income
- 416.35
- Net Income Before Taxes
- 451.13
- Net Income
- 335.4
- Diluted Normalized EPS
- 12.56
- Period
- 2020
- Total Assets
- 3228.36
- Total Liabilities
- 1384.63
- Total Equity
- 1843.72
- Tangible Book Valueper Share Common Eq
- 58.3
- Period
- 2020
- Cashfrom Operating Activities
- 476.19
- Cashfrom Investing Activities
- -160.63
- Cashfrom Financing Activities
- -212.86
- Net Changein Cash
- 102.9
- Period
- 2019
- Total Revenue
- 2279.2
- Selling/ General/ Admin Expenses Total
- 614.24
- Depreciation/ Amortization
- 105.48
- Other Operating Expenses Total
- 7.23
- Total Operating Expense
- 2000.28
- Operating Income
- 278.92
- Net Income Before Taxes
- 325.52
- Net Income
- 236.41
- Diluted Normalized EPS
- 9.29
- Period
- 2019
- Total Assets
- 2982.81
- Total Liabilities
- 1453.34
- Total Equity
- 1529.47
- Tangible Book Valueper Share Common Eq
- 45.64
- Period
- 2019
- Cashfrom Operating Activities
- 262.24
- Cashfrom Investing Activities
- -269.82
- Cashfrom Financing Activities
- -17.43
- Net Changein Cash
- -25.01
- Period
- 2018
- Total Revenue
- 1691.85
- Selling/ General/ Admin Expenses Total
- 434.1
- Depreciation/ Amortization
- 76.2
- Other Operating Expenses Total
- 5.55
- Total Operating Expense
- 1489.57
- Operating Income
- 202.28
- Net Income Before Taxes
- 195.99
- Net Income
- 132.59
- Diluted Normalized EPS
- 5.47
- Period
- 2018
- Total Assets
- 2677.23
- Total Liabilities
- 1373.05
- Total Equity
- 1304.18
- Tangible Book Valueper Share Common Eq
- 39.54
- Period
- 2018
- Cashfrom Operating Activities
- -0.65
- Cashfrom Investing Activities
- -462.31
- Cashfrom Financing Activities
- 528.62
- Net Changein Cash
- 65.66
- Period
- 2017
- Total Revenue
- 1435.25
- Selling/ General/ Admin Expenses Total
- 383.49
- Depreciation/ Amortization
- 71.51
- Other Operating Expenses Total
- 4.87
- Total Operating Expense
- 1202.37
- Operating Income
- 232.88
- Net Income Before Taxes
- 204.99
- Net Income
- 164.52
- Diluted Normalized EPS
- 7.46
- Period
- 2017
- Total Assets
- 1878.72
- Total Liabilities
- 975.12
- Total Equity
- 903.6
- Tangible Book Valueper Share Common Eq
- 30.21
- Period
- 2017
- Cashfrom Operating Activities
- 188.24
- Cashfrom Investing Activities
- -326.09
- Cashfrom Financing Activities
- 55.87
- Net Changein Cash
- -81.98
- Period
- 2022-12-31
- Total Revenue
- 1146.13
- Selling/ General/ Admin Expenses Total
- 119.15
- Depreciation/ Amortization
- 48.36
- Other Operating Expenses Total
- 203.93
- Total Operating Expense
- 963.2
- Operating Income
- 182.93
- Net Income Before Taxes
- 166.9
- Net Income
- 124.33
- Diluted Normalized EPS
- 5.1
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 1150.73
- Selling/ General/ Admin Expenses Total
- 117.71
- Depreciation/ Amortization
- 44.06
- Other Operating Expenses Total
- 211.61
- Total Operating Expense
- 951.89
- Operating Income
- 198.85
- Net Income Before Taxes
- 190.41
- Net Income
- 145.1
- Diluted Normalized EPS
- 5.82
- Period
- 2022-09-30
- Total Assets
- 4858.08
- Total Liabilities
- 2259.85
- Total Equity
- 2598.23
- Tangible Book Valueper Share Common Eq
- 92.06
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 398.26
- Cashfrom Investing Activities
- -112.35
- Cashfrom Financing Activities
- -76.13
- Net Changein Cash
- 209.99
- Period
- 2022-06-30
- Total Revenue
- 1019.56
- Selling/ General/ Admin Expenses Total
- 108.72
- Depreciation/ Amortization
- 43.36
- Other Operating Expenses Total
- 185.78
- Total Operating Expense
- 851.42
- Operating Income
- 168.14
- Net Income Before Taxes
- 165.87
- Net Income
- 127.57
- Diluted Normalized EPS
- 5.13
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 1029.97
- Selling/ General/ Admin Expenses Total
- 108.16
- Depreciation/ Amortization
- 40.18
- Other Operating Expenses Total
- 203.06
- Total Operating Expense
- 877.46
- Operating Income
- 152.52
- Net Income Before Taxes
- 150.12
- Net Income
- 111
- Diluted Normalized EPS
- 4.47
- Period
- 2022-03-31
- Total Assets
- 4512.9
- Total Liabilities
- 1926.36
- Total Equity
- 2586.53
- Tangible Book Valueper Share Common Eq
- 92.13
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 332.05
- Cashfrom Investing Activities
- -380.11
- Cashfrom Financing Activities
- 190
- Net Changein Cash
- 142.88
- Period
- 2021-12-31
- Total Revenue
- 996.77
- Selling/ General/ Admin Expenses Total
- 105.31
- Depreciation/ Amortization
- 39.23
- Other Operating Expenses Total
- 185.79
- Total Operating Expense
- 862.26
- Operating Income
- 134.51
- Net Income Before Taxes
- 134.78
- Net Income
- 100.88
- Diluted Normalized EPS
- 4.05
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day293.63
- 10 Day303.2
- 20 Day313.29
- 50 Day327.25
- 100 Day335.72
- 300 Day309.61
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Natco Pharma
- 533.75
- 4.35
- 0.82
- 936.5
- 526
- 9660.92
- Eris Lifesciences
- 626.5
- 12.9
- 2.1
- 749.85
- 600.5
- 8334.19
- Granules India
- 290.65
- -0.65
- -0.22
- 381.25
- 227
- 7055.55
- Procter & Gamble Health
- 4079.95
- -22.1
- -0.54
- 5163.55
- 3883
- 6804.25
- Jubilant Pharmova
- 352.65
- 6.2
- 1.79
- 555
- 305.2
- 5482.41
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Natco Pharma
- 71.98
- 2.27
- 13.85
- 23.59
- Eris Lifesciences
- 20.32
- 4.37
- 26.83
- 30.04
- Granules India
- 17.41
- 2.8
- 19.17
- 12.14
- Procter & Gamble Health
- 34.47
- 11.04
- -
- -
- Jubilant Pharmova
- 13.18
- 1.03
- 11.9
- 8.04
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 57.98%
- 140,334,231
- BNP PARIBAS ARBITRAGE
- 2.53%
- 6,127,813
- FIDELITY FUNDS - ASIAN SMALLER COMPANIES POOL
- 2.25%
- 5,439,986
- FIDELITY FUNDS - INDIA FOCUS FUND
- 2%
- 4,845,223
- GOVERNMENT PENSION FUND GLOBAL
- 1.15%
- 2,789,094
- Others
- 14.5%
- 35,091,549
- Others
- 17.54%
- 42,449,331
- ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C
- 1.42%
- 3,448,350
- Others
- 2.49%
- 6,021,972
- MAHIMA STOCKS PRIVATE LIMITED
- 1.11%
- 2,684,695
- Others
- 2.63%
- 6,388,095
- Others
- 3.2%
- 7,743,094
- Others
- 2.38%
- 5,750,094
- BASAVA SANKARA RAO KOLLI
- 1.21%
- 2,926,530
- Others
- 0.63%
- 1,524,554
- Others
- 1.23%
- 2,988,355
- Others
- 0.84%
- 2,036,996
- HUF
- 0.52%
- 1,252,663
- Clearing Members
- 0.17%
- 420,806
- Trusts
- 0%
- 500
- Others
- 0.1%
- 247,797
- Others
- 0.04%
- 100,000
- Others
- 0.02%
- 51,734
- Others
- 0%
- 5,000
- Promoter & Promoter Group Shareholding
- 42.02%
- 101,708,525
- KRISHNA PRASAD CHIGURUPATI
- 34.83%
- 84,299,111
- CHIGURUPATI UMA DEVI
- 3.82%
- 9,240,761
- PRAGNYA CHIGURUPATI
- 0.76%
- 1,842,035
- CHIGURUPATI PRIYANKA
- 0.75%
- 1,818,683
- SUSEELA DEVI CHIGURUPATI
- 0.03%
- 65,000
- NIKHILA REDDY YEDAGURI
- 0.01%
- 29,500
- VENKATA MAHESH KRISHNA NARRA
- 0%
- 5,000
- TYCHE INVESTMENTS PRIVATE LIMITED
- 1.47%
- 3,552,557
- SANTHI SREE RAMANAVARAPU
- 0.35%
- 855,878
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-Jan-23
- Quarterly Results
- 20-Oct-22
- Quarterly Results
- 09-Aug-22
- Quarterly Results & Buy Back of Shares
- 18-May-22
- Audited Results & Final Dividend
- 08-Feb-22
- Quarterly Results & Interim Dividend
- 12-Nov-21
- Quarterly Results & Interim Dividend
- 27-Jul-21
- Quarterly Results & Interim Dividend
- 11-May-21
- Audited Results & Final Dividend
- 28-Jan-21
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 25-Feb-22
- 24-Jan-22
- POM
- 05-Aug-21
- 11-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 18-May-22
- -
- 19-Jul-22
- 0.75
- 08-Feb-22
- 18-Feb-22
- 17-Feb-22
- 0.25
- 12-Nov-21
- 25-Nov-21
- 24-Nov-21
- 0.25
- 27-Jul-21
- 06-Aug-21
- 05-Aug-21
- 0.25
- 11-May-21
- -
- 28-Jul-21
- 0.75
- 28-Jan-21
- 09-Feb-21
- 08-Feb-21
- 0.25
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Granules India
- Industry Biotechnology & Drugs
- ISIN INE101D01020
- BSE Code 532482
- NSE Code GRANULES
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
MANAGEMENT
- Krishna Chigurupati Chairman of the Board, Managing Director, Executive Director
- Kandiraju Rao Chief Executive Officer, Joint Managing Director, Executive Director
- G. S. R. Prasad Chief Operating Officer
- Uma Rao G. Chief Human Resource Officer
- Sanjay Kumar Senior Vice President - Corporate Strategy & Planning
- G. N. Prashanth Senior Vice President & Head Corporate Quality
- Manikandan Ramalingam Senior Vice President & Head Formulation R&D
- Chaitanya Tummala Compliance Officer, Company Secretary
- Harsha Chigurupati Non-Independent Executive Director
- Uma Chigurupati Non-Independent Executive Director
Company Summary
GRANULES INDIA SUMMARY
Granules India is trading 0.22% lower at Rs 290.65 as compared to its last closing price. Granules India has been trading in the price range of 296.0 & 288.0. Granules India has given -8.56% in this year & -5.72% in the last 5 days.
Granules India has TTM P/E ratio 15.5 as compared to the sector P/E of 28.39. There are 8 analysts who have initiated coverage on Granules India. There are 2 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 124.33 Crores in its last quarter.
Listed peers of Granules India include Natco Pharma (0.82%), Eris Lifesciences (2.1%), Granules India (-0.22%) etc.
Granules India has a 42.02% promoter holding & 57.98% public holding.
FAQs about Granules India
Granules India is trading at 290.65 as on 2 Feb, 2023 3:29:38 PM. This is -0.22% lower as compared to its previous closing price of 291.3
The market capitalization of Granules India is 7055.55 Cr as on 2 Feb, 2023 3:29:38 PM.
The average broker rating on Granules India is Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 1 analysts have given a hold rating
- 5 analysts have given a buy rating
- 2 analysts have given a strong buy rating
The 52 wk high for Granules India is 381.25 whereas the 52 wk low is 227.0
Granules India can be analyzed on the following key metrics -
- TTM P/E: 15.5
- Sector P/E: 28.39
- Dividend Yield: 0.26%
- D/E ratio: -
Granules India reported a net profit of 412.76 Cr in 2022.
